Characterization of immunoliposomes as delivery vehicles for the Rac inhibitor Ehop-016 in HER2 type breast cancer

被引：0
|
作者：
Rivera-Robles, Michael J.
Vivas-Mejia, Pablo E.
Castillo-Pichardo, Linette
Vlaar, Cornelis
Hernandez, Eliud
Dharmawardhane, Suranganie
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-2197
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2197
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer
    Luis D. Borrero-García
    Maria del Mar Maldonado
    Julia Medina-Velázquez
    Angel L. Troche-Torres
    Luis Velazquez
    Nilmary Grafals-Ruiz
    Suranganie Dharmawardhane
    BMC Cancer, 21
  • [22] Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer
    Borrero-Garcia, Luis D.
    del Mar Maldonado, Maria
    Medina-Velazquez, Julia
    Troche-Torres, Angel L.
    Velazquez, Luis
    Grafals-Ruiz, Nilmary
    Dharmawardhane, Suranganie
    BMC CANCER, 2021, 21 (01)
  • [23] Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity
    Hanker, Ariella B.
    Jayanthan, Harikrishna Sekar
    Ye, Dan
    Lin, Chang-Ching
    Akamatsu, Hiroaki
    Sheehan, Jonathan H.
    Koch, James P.
    Sudhan, Dhivya R.
    Brewer, Monica Red
    Servetto, Alberto
    He, Jie
    Miller, Vincent A.
    Lalani, Alshad S.
    Meiler, Jens
    Arteaga, Carlos L.
    CANCER RESEARCH, 2020, 80 (04)
  • [24] SCREENING OF NOVEL INHIBITOR FOR HER2 INDUCED BREAST CANCER-AN INSILICO APPROACH
    Rupani, Amit R.
    Bhattacharjee, Biplabh
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2011, 2 (01): : 153 - 159
  • [25] HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer
    Harbeck, Nadia
    Beckmann, Matthias W.
    Rody, Achim
    Schneeweiss, Andreas
    Mueller, Volkmar
    Fehm, Tanja
    Marschner, Norbert
    Gluz, Oleg
    Schrader, Iris
    Heinrich, Georg
    Untch, Michael
    Jackisch, Christian
    BREAST CARE, 2013, 8 (01) : 49 - 55
  • [26] Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor
    Andreani, Cristina
    Bartolacci, Caterina
    Wijnant, Kathleen
    Crinelli, Rita
    Bianchi, Marzia
    Magnani, Mauro
    Hysi, Albana
    Iezzi, Manuela
    Amici, Augusto
    Marchini, Cristina
    AGING-US, 2017, 9 (02): : 508 - 523
  • [27] Trastuzumab for patients with HER2 positive breast cancer: Delivery, duration and combination therapies
    Pinto, Ana Catarina
    Ades, Felipe
    de Azambuja, Evandro
    Piccart-Gebhart, Martine
    BREAST, 2013, 22 : S152 - S155
  • [28] Nanoparticle delivery of TFOs is a novel targeted therapy for HER2 amplified breast cancer
    Yang, Xiaojing
    Xu, Yi
    Fu, Jie
    Shen, Zan
    BMC CANCER, 2023, 23 (01)
  • [29] Proteomic characterization of Her2/neu-overexpressing breast cancer cells
    Chen, Hexin
    Pimienta, Genaro
    Gu, Yiben
    Sun, Xu
    Hu, Jianjun
    Kim, Min-Sik
    Chaerkady, Raghothama
    Gucek, Marjan
    Cole, Robert N.
    Sukumar, Saraswati
    Pandey, Akhilesh
    PROTEOMICS, 2010, 10 (21) : 3800 - 3810
  • [30] HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
    Popovic, Marina
    Silovski, Tajana
    Krizic, Marija
    Plavetic, Natalija Dedic
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (09)
12345